QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTD



Comments are closed.

Dolby Family Ventures invests in Cortexyme and PharmatrophiX
System1 Announces $25 Million Series A Funding
Tempo Automation completes SPAC transaction and begins trading on NASDAQ under ticker TMPO
Phase Four Partners with Redwire to Expand Space Propulsion Offerings and Deliver Hall Effect Thrusters